#USA #New York #Pomerantz LLP #Acadia Pharmaceuticals #ACAD

Acadia Pharmaceuticals Under Investigation by Pomerantz Law Firm

The renowned Pomerantz Law Firm is actively probing into claims concerning investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). This investigation is primarily focused on whether the company and some of its top executives may have engaged in securities fraud or other illicit business practices that could have affected shareholders adversely.

Background of the Investigation

On October 23, 2025, Pomerantz announced its investigation amid growing concerns among investors. The situation escalated significantly following a press release from ACADIA on September 24, 2025. This announcement disclosed the results of the Phase 3 COMPASS PWS trial, which was focused on evaluating the safety and effectiveness of intranasal carbetocin (ACP-101) in treating hyperphagia in Prader-Willi syndrome (PWS).

The trial results were disappointing, revealing that the medication did not show a statistically significant improvement compared to a placebo on the primary endpoint. Furthermore, there was no separation from the placebo group on any secondary endpoints either. This revelation led the Head of Research and Development at Acadia to state that the company would not pursue further investigation of this drug due to the unfavorable outcomes.

Market Reaction

As a direct consequence of the trial's results, ACAD's stock experienced a substantial drop. On the announcement day, shares plummeted by $2.34 each, constituting a staggering 9.92% decrease, bringing the closing price down to $21.26 per share. Such strong market reactions raise concern among investors regarding the company's transparency and communication practices.

The Role of Pomerantz LLP

Pomerantz LLP is not new to handling complex securities litigation. With offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has established itself as a leader in corporate and securities class action cases. Founded over 85 years ago by Abraham L. Pomerantz, the firm has been at the forefront of championing the rights of victims who have suffered due to corporate malfeasance.

The firm has a long history of recovering large damages for their clients and continues to uphold the principles of justice in the financial markets. Investors who feel they may have been wronged by ACADIA Pharmaceuticals are encouraged to reach out to Pomerantz for further guidance and potential legal recourse.

How to Get Involved

Investors interested in participating in this investigation can directly contact Danielle Peyton at Pomerantz LLP via email at [email protected] or via phone at 646-581-9980, ext. 7980. The firm is dedicated to uncovering the truth behind any potential misconduct that could have adversely impacted shareholders.

Conclusion

With increasing scrutiny over corporate practices and governance, the investigation by Pomerantz LLP into ACADIA Pharmaceuticals serves as a reminder of the importance of transparency in the biotech sector. Investors should remain vigilant and informed as the situation develops. As legal discussions progress, shareholders are reminded to seek professional advice and stay updated on further announcements from both ACADIA Pharmaceuticals and Pomerantz LLP.